Moleculin Biotech (MBRX) News Today $0.95 +0.01 (+1.20%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.93 -0.02 (-2.21%) As of 05/23/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Roth Capital Has Positive Estimate for MBRX Q2 EarningsMay 18, 2025 | americanbankingnews.comEarnings call transcript: Moleculin Biotech reports Q1 2025 updatesMay 15, 2025 | uk.investing.comMOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly EarningsMay 15, 2025 | nasdaq.comMoleculin Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical TrialMay 12, 2025 | finanznachrichten.deMoleculin Biotech, Inc. Expands Phase 3 Trial of Annamycin for R/R AML to Nine EU Countries, Enrollment UnderwayMay 12, 2025 | quiverquant.comMoleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical TrialMay 12, 2025 | globenewswire.comMoleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and WebcastMay 7, 2025 | globenewswire.comMoleculin secures two new US patents for cancer drug AnnamycinMay 6, 2025 | investing.comMoleculin Biotech, Inc. Announces INN Approval for Annamycin as Pivotal Phase 3 Trial Advances in AML TreatmentMay 6, 2025 | quiverquant.comMoleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for AnnamycinMay 6, 2025 | globenewswire.comMoleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. PatentsMay 5, 2025 | globenewswire.comMoleculin reports Annamycin cancer drug synergy at AACR meetingApril 30, 2025 | investing.comMoleculin Biotech Presents Promising Annamycin Data at AACR Annual Meeting 2025, Highlighting Synergistic Potential with FDA Approved Cancer TherapiesApril 30, 2025 | nasdaq.comMoleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic CancerApril 29, 2025 | globenewswire.comMoleculin Biotech Releases Corporate Presentation OnlineApril 21, 2025 | tipranks.comMoleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025April 17, 2025 | globenewswire.comMoleculin Biotech doses first patient in Phase 3 MIRACLE trialApril 2, 2025 | finance.yahoo.comMoleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE TrialApril 1, 2025 | globenewswire.comMoleculin Biotech files to sell 18.2M shares of common stock for holdersMarch 31, 2025 | markets.businessinsider.comMoleculin Biotech upgraded to Buy from Hold at MaximMarch 27, 2025 | markets.businessinsider.comEarnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trialsMarch 26, 2025 | uk.investing.comMaxim Group Upgrades Moleculin Biotech (MBRX)March 26, 2025 | msn.comMoleculin biotech highlights pivotal Phase 3 trials for Annamycin in AML with interim results expected in 2025March 25, 2025 | msn.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comMoleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comMoleculin Biotech Shares Corporate Presentation UpdateMarch 24, 2025 | tipranks.comMoleculin Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 24, 2025 | globenewswire.comMoleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and WebcastMarch 19, 2025 | globenewswire.comMoleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand ConferenceMarch 11, 2025 | prnewswire.comMoleculin to Present at the 37th Annual ROTH ConferenceMarch 10, 2025 | prnewswire.comMoleculin Biotech to be granted new patents for AnnamycinMarch 6, 2025 | markets.businessinsider.comMoleculin Announces Additional Annamycin Patent Allowances to Enhance Global ExclusivityMarch 6, 2025 | prnewswire.comMoleculin Biotech target adjusted to $8 from $45 at H.C. WainwrightMarch 3, 2025 | markets.businessinsider.comMoleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International SymposiumMarch 3, 2025 | prnewswire.comMoleculin Biotech announces pricing of $3.5M registered direct offeringFebruary 25, 2025 | markets.businessinsider.comMoleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq RulesFebruary 25, 2025 | prnewswire.comMoleculin Biotech (NASDAQ:MBRX) Stock, Short Interest ReportFebruary 14, 2025 | benzinga.comMoleculin Biotech secures $5.8 million from warrant exerciseFebruary 13, 2025 | msn.comWhy Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?February 13, 2025 | benzinga.comMoleculin Announces Exercise of Warrants for $5.8 Million Gross ProceedsFebruary 13, 2025 | prnewswire.comMoleculin Biotech receives positive FDA guidance for acceleration of AML trialFebruary 13, 2025 | markets.businessinsider.comMoleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)February 13, 2025 | prnewswire.comMoleculin Biotech downgraded to Hold from Buy at MaximFebruary 13, 2025 | markets.businessinsider.comMoleculin Announces First European Approval for Phase 3 AML TrialFebruary 11, 2025 | msn.comMoleculin Biotech receives first approval in Europe for AML trial recruitingFebruary 11, 2025 | markets.businessinsider.comMoleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal TrialFebruary 11, 2025 | prnewswire.comMoleculin Biotech reaches agreement to amend investor warrantsFebruary 10, 2025 | msn.comMBRX stock touches 52-week low at $1.46 amid sharp yearly declineJanuary 30, 2025 | msn.comMoleculin Participates in Virtual Investor "What This Means" SegmentJanuary 27, 2025 | prnewswire.com Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼1.060.75▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼01▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMRX News Today OKYO News Today IKNA News Today CUE News Today PRLD News Today ATNM News Today CELU News Today STTK News Today HOWL News Today RENB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBRX Stock Free MBRX Stock Alerts